1. Venturini E, Turkova A, Chiappini E, et al. Tuberculosis and HIV co-infection in children. BMC Infect Dis 2014; 14 (Suppl 1): S5.
2. Pillay T, Khan M, Moodley J, et al. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis 2004 March; 4: 155–165.
3. Schaaf HS, Thee S, van der Laan L, et al. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf 2016 Oct; 15 (10).
4. Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet 2014 Jun; 53 (6): 489–507.
5. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14 (8): 1039–1043.
6. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007; 12 (4): 515–521.